318 related articles for article (PubMed ID: 20083225)
1. MicroRNAs in ovarian cancer biology and therapy resistance.
van Jaarsveld MT; Helleman J; Berns EM; Wiemer EA
Int J Biochem Cell Biol; 2010 Aug; 42(8):1282-90. PubMed ID: 20083225
[TBL] [Abstract][Full Text] [Related]
2. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
3. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
4. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications.
Mezzanzanica D; Bagnoli M; De Cecco L; Valeri B; Canevari S
Int J Biochem Cell Biol; 2010 Aug; 42(8):1262-72. PubMed ID: 20035894
[TBL] [Abstract][Full Text] [Related]
5. Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs.
Helleman J; Jansen MP; Burger C; van der Burg ME; Berns EM
Int J Biochem Cell Biol; 2010 Jan; 42(1):25-30. PubMed ID: 19854294
[TBL] [Abstract][Full Text] [Related]
6. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
7. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
Yang L; Li N; Wang H; Jia X; Wang X; Luo J
Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
[TBL] [Abstract][Full Text] [Related]
8. [Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer].
Yang LY; Wang HJ; Jia XB; Wang X; Luo J; Zhang XY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):60-4. PubMed ID: 22455133
[TBL] [Abstract][Full Text] [Related]
9. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer.
Hu X; Macdonald DM; Huettner PC; Feng Z; El Naqa IM; Schwarz JK; Mutch DG; Grigsby PW; Powell SN; Wang X
Gynecol Oncol; 2009 Sep; 114(3):457-64. PubMed ID: 19501389
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA expression profiles in serous ovarian carcinoma.
Nam EJ; Yoon H; Kim SW; Kim H; Kim YT; Kim JH; Kim JW; Kim S
Clin Cancer Res; 2008 May; 14(9):2690-5. PubMed ID: 18451233
[TBL] [Abstract][Full Text] [Related]
11. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
12. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.
Chan JK; Blansit K; Kiet T; Sherman A; Wong G; Earle C; Bourguignon LY
Gynecol Oncol; 2014 Mar; 132(3):739-44. PubMed ID: 24472409
[TBL] [Abstract][Full Text] [Related]
13. New players in ovarian cancer.
Bovicelli A; D'Andrilli G; Giordano A
J Cell Physiol; 2011 Oct; 226(10):2500-4. PubMed ID: 21302305
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy.
Cho WC
Int J Biochem Cell Biol; 2010 Aug; 42(8):1273-81. PubMed ID: 20026422
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics.
Koutsaki M; Spandidos DA; Zaravinos A
Cancer Lett; 2014 Sep; 351(2):173-81. PubMed ID: 24952258
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR].
Cui XY; Guo YJ; Yao HR
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1813-5. PubMed ID: 18971180
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.
Guo L; Liu Y; Bai Y; Sun Y; Xiao F; Guo Y
Eur J Cancer; 2010 Jun; 46(9):1692-702. PubMed ID: 20371173
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells.
Chen J; Wang L; Matyunina LV; Hill CG; McDonald JF
Gynecol Oncol; 2011 Apr; 121(1):200-5. PubMed ID: 21277012
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1.
Guo LM; Pu Y; Han Z; Liu T; Li YX; Liu M; Li X; Tang H
FEBS J; 2009 Oct; 276(19):5537-46. PubMed ID: 19702828
[TBL] [Abstract][Full Text] [Related]
20. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture.
Helleman J; Smid M; Jansen MP; van der Burg ME; Berns EM
Gynecol Oncol; 2010 May; 117(2):170-6. PubMed ID: 20132968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
